Skip to main content

Advertisement

Table 2 SVR12 according to patient baseline characteristics (ITT population)

From: Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

n/N (%) Phase 2/3 group (N = 125) Phase 1 group (N = 16)a
HCV geno/subtype
 1a 33/50 (66.0) 5/14 (35.7)
  with baseline Q80K 8/12 (66.7) 2/3 (66.7)
  without baseline Q80K 25/38 (65.8) 3/11 (27.3)
 1b 54/75 (72.0) 1/2 (50.0)
IL28B
 CC 17/20 (85.0) 1/1 (100.0)
 CT 58/87 (66.7) 3/9 (33.3)
 TT 12/18 (66.7) 2/6 (33.3)
HOMA-IR
  <2 39/46 (84.8) 2/4 (50.0)
  ≥2 to ≤4 25/43 (58.1) 3/7 (42.9)
  >4 20/31 (64.5) 0/3
METAVIR fibrosis score
 F0–F2 64/85 (75.3) 5/13 (38.5)
 F3–F4 23/40 (57.5) 1/3 (33.3)
 F3 11/18 (61.1) 1/3 (33.3)
 F4 12/22 (54.5) 0
  1. aDue to small patient numbers, these data should be interpreted with caution
  2. HCV hepatitis C virus, HOMA-IR homeostatic model assessment of insulin resistance, IL28B interleukin-28b, ITT intent-to-treat, SVR12 sustained virologic response 12 weeks after planned end of treatment